QBFM
NKTR icon

QS Batterymarch Financial Management’s Nektar Therapeutics NKTR Stock Holding History

QS Batterymarch Financial Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$435K Sell
2,403
-246
-9% -$47.1K 0.01% 602
2014
Q2 		$510K Sell
2,649
-223
-8% -$39.4K 0.01% 588
2014
Q1 		$523K Buy
2,872
+1,272
+80% +$252K 0.01% 730
2013
Q4 		$273K Buy
+1,600
New +$258K 0.01% 810

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

QS Batterymarch Financial Management's NKTR Position: Q3 2014 in Review

QS Batterymarch Financial Management reduced its Nektar Therapeutics (NKTR) stake by 9.3% in Q3 2014, selling an estimated $47.1K and leaving 2,403 shares worth $435K. The position accounts for 0.01% of the portfolio, ranked #602.

QS Batterymarch Financial Management first reported a position in NKTR in Q4 2013 and has held it in 4 quarters since. The position peaked at $523K in Q1 2014. 145 funds tracked by Wall St. Rank hold NKTR as of Q3 2014.

  • QS Batterymarch Financial Management held 2,403 shares of Nektar Therapeutics worth $435K as of Q3 2014.
  • QS Batterymarch Financial Management sold 246 Nektar Therapeutics shares in Q3 2014, an estimated $47.1K.
  • Nektar Therapeutics made up 0.01% of QS Batterymarch Financial Management's portfolio in Q3 2014, its #602 holding.
  • QS Batterymarch Financial Management first reported a position in Nektar Therapeutics in Q4 2013 and has held it in 4 quarters since.
  • QS Batterymarch Financial Management's Nektar Therapeutics position peaked at $523K in Q1 2014.
  • 145 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2014.

Based on QS Batterymarch Financial Management's 13F filing for Q3 2014, filed 14 Nov 2014.